Report Sees 'Cognitive Dissonance' In Mylan's Internal Price Target By: Benzinga via Benzinga May 04, 2015 at 16:30 PM EDT Mylan NV (NASDAQ: MYL) told a would-be buyer recently that it's worth more than $100 a share, yet the company's current ... Read More >> Related Stocks: Macy's Mylan Teva Pharmaceutical Industries ADR